Champions Oncology Future Growth

NasdaqCM:CSBR - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
4/30/2026	59	N/A	-3	N/A	1
4/30/2025	54	N/A	-7	N/A	1
4/30/2024	49	N/A	-8	N/A	1
1/31/2024	49	-10	-7	-5	N/A
10/31/2023	50	-10	-5	-3	N/A
7/31/2023	53	-8	-3	0	N/A
4/30/2023	54	-5	1	4	N/A
1/31/2023	54	-3	3	5	N/A
10/31/2022	54	0	6	8	N/A
7/31/2022	52	0	4	6	N/A
4/30/2022	49	1	4	6	N/A
1/31/2022	47	0	1	4	N/A
10/31/2021	44	0	-4	0	N/A
7/31/2021	43	0	-4	-1	N/A
4/30/2021	41	0	-5	-2	N/A
1/31/2021	39	-1	-1	3	N/A
10/31/2020	37	-2	0	3	N/A
7/31/2020	35	-1	0	2	N/A
4/30/2020	32	-2	1	3	N/A
1/31/2020	31	0	0	1	N/A
10/31/2019	29	-1	1	2	N/A
7/31/2019	28	-1	0	1	N/A
4/30/2019	27	0	1	2	N/A
1/31/2019	24	0	1	2	N/A
10/31/2018	23	0	0	1	N/A
7/31/2018	21	0	1	1	N/A
4/30/2018	20	-1	-2	-1	N/A
1/31/2018	19	-3	-2	-1	N/A
10/31/2017	18	-5	N/A	-2	N/A
7/31/2017	17	-5	N/A	-2	N/A
4/30/2017	15	-7	N/A	-3	N/A
1/31/2017	15	-7	N/A	-4	N/A
10/31/2016	14	-8	N/A	-4	N/A
7/31/2016	12	-10	N/A	-6	N/A
4/30/2016	11	-10	N/A	-6	N/A
1/31/2016	12	-12	N/A	-8	N/A
10/31/2015	11	-12	N/A	-10	N/A
7/31/2015	10	-13	N/A	-9	N/A
4/30/2015	9	-13	N/A	-10	N/A
1/31/2015	8	-12	N/A	-7	N/A
10/31/2014	10	-10	N/A	-7	N/A
7/31/2014	10	-9	N/A	-4	N/A
4/30/2014	12	-7	N/A	-3	N/A
1/31/2014	11	-7	N/A	-5	N/A
10/31/2013	10	-8	N/A	-4	N/A
7/31/2013	9	-7	N/A	-5	N/A
4/30/2013	8	-6	N/A	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CSBR's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if CSBR's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if CSBR's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CSBR's revenue (10.8% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: CSBR's revenue (10.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CSBR's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Champions Oncology Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Consensus EPS estimates upgraded to US$0.49 loss

Consensus EPS estimates fall by 33%

Consensus EPS estimates have been downgraded.

Price target decreased to US$13.67

Consensus EPS estimates increase by 100%

Consensus forecasts updated

Recent updates

Third quarter 2024 earnings released: US$0.19 loss per share (vs US$0.18 loss in 3Q 2023)

Champions Oncology, Inc. to Report Q3, 2024 Results on Mar 12, 2024

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Champions Oncology, Inc. to Report Q2, 2024 Results on Dec 12, 2023

Champions Oncology, Inc. Appoints Brady Davis as President

Independent Director recently bought US$97k worth of stock

Consensus EPS estimates upgraded to US$0.49 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Champions Oncology, Inc. to Report Q1, 2024 Results on Sep 13, 2023

Champions Oncology, Inc., Annual General Meeting, Oct 19, 2023

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS misses analyst expectations

Champions Oncology, Inc. to Report Q4, 2023 Results on Jul 24, 2023

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 33%

Consensus EPS estimates have been downgraded.

Price target decreased to US$13.67

Champions Oncology, Inc. to Report Q2, 2023 Results on Dec 13, 2022

Insufficient new directors

Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?

Consensus EPS estimates increase by 100%

Champions Oncology, Inc. to Report Q1, 2023 Results on Sep 08, 2022

Champions Oncology, Inc., Annual General Meeting, Oct 20, 2022

Consensus forecasts updated

Full year 2022 earnings released: EPS: US$0.042 (vs US$0.028 in FY 2021)

Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation

First quarter 2022 earnings released: US$0.013 loss per share (vs US$0.006 profit in 1Q 2021)

Full year 2021 earnings released: EPS US$0.025 (vs US$0.17 loss in FY 2020)

Champions Oncology, Inc.(NasdaqCM:CSBR) dropped from Russell 2500 Growth Index

We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth

Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?

Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation

Price target increased to US$15.00

Revenue and earnings beat expectations

Third quarter 2021 earnings released: EPS US$0.055 (vs US$0.035 in 3Q 2020)

New 90-day high: US$12.21

The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?

Independent Director has left the company

Champions Oncology, Inc. Announces Resignation of Abba David Poliakoff as Board of Director

Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?

Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?

Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares

Board Member recently sold US$357k worth of stock

Price target raised to US$12.83

Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results

Champions Oncology, Inc. Revises Revenue Guidance for the Year 2021

Champions Oncology beats on revenue

Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)

New 90-day high: US$9.99

Champions Oncology, Inc. to Report Q1, 2021 Results on Sep 14, 2020

First quarter earnings released

New 90-day low - US$7.05

New 90-day low - US$8.28

New 90-day high - US$9.96

Champions Oncology, Inc.(NasdaqCM:CSBR) dropped from Russell Microcap Value Index

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies